DrugPatentWatch Archives
Click here to return to the current data set
|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: APIDRA
Summary for Tradename: APIDRA
|
| |||||||||
Clinical Trials for: APIDRAComparison of Apidra to Regular Insulin in Hospitalized Patients Status: Active, not recruiting Condition: Diabetes Mellitus, Type II Insulin Glargine "All to Target" Trial Status: Completed Condition: Diabetes Mellitus, Type 2 Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents Status: Terminated Condition: Diabetes Type 1 Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin Status: Completed Condition: Diabetes Mellitus, Type 2 Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy Volunteers Status: Completed Condition: Diabetes Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients Status: Recruiting Condition: Type 2 Diabetes The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children Status: Recruiting Condition: Type 1 Diabetes Mellitus Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart Status: Completed Condition: Type 2 Diabetes Mellitus Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes Status: Recruiting Condition: Diabetes During Pregnancy Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction Status: Terminated Condition: AMI Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Exclusivity Expiration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | APIDRA | insulin glulisine recombinant | INJECTABLE; IV (INFUSION)-SC | 021629 | Apr 16, 2004 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | APIDRA | insulin glulisine recombinant | INJECTABLE; IV (INFUSION)-SC | 021629 | Apr 16, 2004 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | APIDRA | insulin glulisine recombinant | INJECTABLE; IV (INFUSION)-SC | 021629 | Apr 16, 2004 | RX | Yes | 6,221,633 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sanofi Aventis Us | APIDRA | insulin glulisine recombinant | INJECTABLE; IV (INFUSION)-SC | 021629 | Apr 16, 2004 | RX | Yes | 6,960,561 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc